EP02.04-007. Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
Back to course
Pdf Summary
Asset Subtitle
Patrick M Forde
Meta Tag
Speaker Patrick M Forde
Topic Early Stage Non-small Cell Lung Cancer - Systemic Therapy
Keywords
Neo-KAN
neoadjuvant therapy
adagrasib
MRTX849
nivolumab
non-small cell lung cancer
surgery
pCR rate
chemotherapy
genomic features
Powered By